| Stereochemistry | ABSOLUTE |
| Molecular Formula | C78H98N4O20 |
| Molecular Weight | 1411.6275 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 6 / 6 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC[C@H](C(=O)N1CCCC[C@H]1C(=O)O[C@H](CCC2=CC=C(OC)C(OC)=C2)C3=CC=CC(OCC(=O)NCCNC(=O)COC4=CC=CC(=C4)[C@@H](CCC5=CC(OC)=C(OC)C=C5)OC(=O)[C@@H]6CCCCN6C(=O)[C@@H](CC)C7=CC(OC)=C(OC)C(OC)=C7)=C3)C8=CC(OC)=C(OC)C(OC)=C8
InChI
InChIKey=GQLCLPLEEOUJQC-ZTQDTCGGSA-N
InChI=1S/C78H98N4O20/c1-13-57(53-43-67(93-7)73(97-11)68(44-53)94-8)75(85)81-37-17-15-25-59(81)77(87)101-61(31-27-49-29-33-63(89-3)65(39-49)91-5)51-21-19-23-55(41-51)99-47-71(83)79-35-36-80-72(84)48-100-56-24-20-22-52(42-56)62(32-28-50-30-34-64(90-4)66(40-50)92-6)102-78(88)60-26-16-18-38-82(60)76(86)58(14-2)54-45-69(95-9)74(98-12)70(46-54)96-10/h19-24,29-30,33-34,39-46,57-62H,13-18,25-28,31-32,35-38,47-48H2,1-12H3,(H,79,83)(H,80,84)/t57-,58-,59-,60-,61+,62+/m0/s1
| Molecular Formula | C78H98N4O20 |
| Molecular Weight | 1411.6275 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 6 / 6 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Rimiducid (AP1903) is a lipid-permeable tacrolimus analogue with homodimerizing activity. Rimiducid homodimerizes an analogue of human protein FKBP12 (Fv) which contains a single acid substitution (Phe36Val). This agent is used to homodimerize the Fv-containing drug-binding domains of genetically engineered proteins such as the iCD40 receptor, Fas intracellular domain or iCaspase 9 resulting in downstream signaling activation during cell therapy. Orphan designation was granted for rimiducid (AP1903) for the treatment of graft-versus-host disease.
Originator
Approval Year
Doses
AEs
Sourcing
PubMed
Patents
Sample Use Guides
Twenty-eight normal healthy male volunteers were randomized into five dosage groups of AP1903 (0.01, 0.05, 0.1, 0.5, and 1 mg/kg)
Route of Administration:
Intravenous
The human fibrosarcoma line HT1080 was engineered to express stably a fusion protein comprising a myristoylation sequence, two copies of F36V-FKBP, and the human Fas intracellular domain. Rimiducid (AP1903) elicited potent and dose-dependent apoptotic death of these engineered cells in culture, with an EC50 of ~0.1 nM
